01—Abstract
Summary
Summary of the 8-K filed October 31, 2024. Cited figures are marked; the original filing is the authoritative source.
IDEXX Laboratories reported third quarter 2024 results on October 31, 2024: revenue of $976 milliona, up 7% as reported and 6% organic, with CAG Diagnostics recurring revenue up 7% as reported and organic.
Diluted EPS was $2.80b, up 11% as reported and 12% on a comparable basis, and operating margin expanded 110 basis points to 31.2%. Growth was supported by double-digit growth in the premium installed base, international strength, and high-growth IDEXX VetLab consumables (+11%) and Water (+13%), while Livestock, Poultry and Dairy declined 3%. The key item for investors is the guidance cut.
Full-year 2024 revenue guidance was lowered to $3,865 million to $3,890 millionc, a reduction of $38 million at the midpoint (about 1%), and organic growth guidance was reduced to 5.3% to 6.0%. Management attributed the change to macro and sector conditions that are constraining pet owner visits and demand at U.S. veterinary clinics. Full-year EPS guidance was narrowed to $10.37 to $10.53, which keeps the midpoint unchanged, and the operating margin outlook of 28.7% to 29.0% was maintained.
The quarter also reflects a large one-time charge. In the second quarter, the company recorded a $61.5 milliond discrete litigation accrual related to alleged underpayment of royalties under an expired patent license, bringing the total accrual to $89.0 million. This is a roughly $0.56 per-share hit to 2024 EPS and about 160 basis points of reported operating margin.
Management also highlighted nearly 700 pre-orders for the inVue Dx Cellular Analyzer, which begins shipping in the fourth quarter. Free cash flow for the first nine months was $575 million, and the company repurchased $591 million of stock during that period.
02—Key points
Key Highlights
- Q3 2024 revenue of $975.5 million grew 6.6% as reported and 6.1% organically, driven by CAG growth of 7% (6% organic).
- Q3 diluted EPS of $2.80 rose 11% as reported and 12% on a comparable basis; operating margin expanded 110 bps to 31.2%.
- Full-year 2024 revenue guidance was cut by $38 million at the midpoint to $3,865M-$3,890M, reflecting weaker U.S. clinical visit trends; organic growth guidance is now 5.3%-6.0%, down from 6.2%-7.8%.
- Full-year 2024 EPS guidance was narrowed to $10.37-$10.53, with the midpoint unchanged despite the revenue reduction, helped by lower interest expense and tax rate.
- A $61.5 million Q2 litigation accrual (total $89.0 million) weighs on 2024 results, reducing EPS by about $0.56 and reported operating margin by about 160 bps.
- Growth was led by IDEXX VetLab consumables (+11%), Water (+13%), and a 10% increase in the global premium instrument installed base; U.S. CAG Diagnostics recurring revenue grew 5%.
- Free cash flow for the first nine months was $575 million, and the company repurchased $591 million of stock year to date.
03—Questions
Frequently Asked Questions
Why did IDEXX lower its 2024 revenue guidance if EPS guidance held steady?
The revenue cut of about $38 million at the midpoint reflects weaker U.S. veterinary clinic visit and demand trends. Management offset the impact on EPS with a favorable foreign exchange update of about $0.02, lower projected interest expense, and a lower effective tax rate, so the EPS midpoint was unchanged. The company still expects a consistent operating margin of 28.7%-29.0%.
What is the ongoing litigation matter and how large is the exposure?
IDEXX is a defendant in a breach of contract suit alleging underpayment of royalties from 2004 through 2017 under an expired patent license. The company has accrued $89.0 million, including a $61.5 million charge in Q2 2024, as its best estimate of probable loss. The final outcome could be higher or lower than the accrual.
How did the core businesses perform in the quarter?
CAG Diagnostics recurring revenue grew 7% reported and organically, with international growth at 10%. IDEXX VetLab consumables rose 11%, and rapid assay products grew 6%. Reference lab services grew 3%. Water revenue increased 13%, while Livestock, Poultry and Dairy declined 3%, mainly due to lower Asia Pacific swine testing.
Is margin expansion sustainable despite the revenue slowdown?
Q3 operating margin expanded 110 bps to 31.2%, helped by business mix toward high-margin consumables and software recurring revenue, plus lower instrument costs. Management maintained its full-year operating margin outlook, but it noted that the lapping of a 2023 customer contract payment will create a roughly 40 bps headwind for the full-year comparable margin expansion.
What growth catalysts did management highlight?
Management pointed to the inVue Dx Cellular Analyzer, which had nearly 700 pre-orders and begins shipping in Q4 2024. It also cited continued placements of cloud-based software, growth in the premium installed base, and net price realization improvements. These are intended to offset the near-term pressure from weaker U.S. clinic visit trends.
04—Continue